Measuring health related quality of life in lung cancer clinical trials - Anoverview of the database ClinicalTrials.gov;Lebensqualitätsmessung in klinischen Studien beim Lungenkarzinom - Übersicht anhand der Datenbank ClinicalTrials.gov

PharmacoEconomics - German Research Articles

Volumn 10, Issue 1, 2012, Pages 3-15

  Damm, Kathrin ^a   Jacob, Christian ^b   Mittendorf, Thomas ^b   Von Der Schulenburg, J Matthias Graf ^a  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b Health Economic Research and Consulting   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); FACTUAL DATABASE; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW;

EID: 84859084998     PISSN: 16123727     EISSN: 1868677X     Source Type: Journal    
DOI: 10.2165/11589820     Document Type: Review

References (25)

1. Robert Koch Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V.Krebs in Deutschland 2005/ 2006. Häufigkeiten und Trends. 7. Ausgabe, Berlin, 2010: 48
2. Ullmann U. Lebensqualität nach Diagnose Lungenkrebs. Edition Wissenschaft: Reihe Psychologie 73. Jg., Marburg: Tectum-Verlag, 2001: 21-4
3. Zabernigg A. Neues in der Behandlung des nicht-kleinzelligen Bronchialkarzinoms im Stadium IIIB (Pleuraerguss) und IV. Wien Med Wochenschr 2007; 157 (21-22): 536-9 (Pubitemid 350304137)
4. Liu J, Mittendorf T, von der Schulenburg JM. A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia. Cancer Invest 2010; 28 (3): 312-22
5. Di Maio M, Gallo C, De Maio E, et al. Methodological aspects of lung cancer clinical trials in the era of targeted agents. Lung Cancer 2010; 67 (2): 127-35
6. Food andDrugAdministration (FDA).Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, 2009. Erhä ltlich unter URL: GuidanceComplianceRegulatoryInformation/ Guidances/ UCM193282.pdf [Abgerufen 01.12.11]
7. Pirker R. Endpoints in Clinical Trials. Lung Cancer 2009; 64 Suppl. 1: 22
8. Reck M. Quality of Life as an Endpoint of Clinical Trials. Lung Cancer 2009; 64 Suppl. 1: 22-3
9. Vansteenkiste J. Is there a preferred Endpoint? Lung Cancer 2009; 64 Suppl. 1: 22
10. Camps C, del Pozo N, Blasco A, et al. Importance of quality of life in patients with non-small-cell lung cancer. Clin Lung Cancer 2009; 10 (2): 83-90
11. Holzner B, Kemmler G, Greil R, et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 2002; 13 (6): 965-73 (Pubitemid 34752693)
12. Okuyama T, Akechi T, Kugaya A, et al. Development and validation of the cancer fatigue scale: A brief, threedimensional, self-rating scale for assessment of fatigue in cancer patients. J Pain Symptom Manage 2000; 19 (1): 5-14 (Pubitemid 30067618)
13. Radbruch L, Sabatowski R, Elsner F, et al. Validation of the German version of the brief fatigue inventory. J Pain Symptom Manage 2003; 25 (5): 449-58 (Pubitemid 36506674)
14. Johnston M, Pollard B, Hennessey P. Construct validation of the hospital anxiety and depression scale with clinical populations. J Psychosom Res 2000; 48 (6): 579-84
15. Tanaka K, Akechi T, Okuyama T, et al. Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale. Br J Cancer 2000; 82 (4): 800-5 (Pubitemid 30085229)
16. Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994; 30A (5): 635-42 (Pubitemid 24164250)
17. Browning KK, Ferketich AK, Otterson GA, et al. A psychometric analysis of quality of life tools in lung cancer patients who smoke. Lung Cancer 2009 Oct; 66 (1): 134-9
18. Siewert JR, Rothmund M, Schumpelick V. Praxis der Viszeralchirurgie. Onkologische Chirurgie, 3. Aufl. Heidelberg: Springer, 2010: 402
19. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy- Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12 (3): 199-220
20. ClinicalTrials.gov. About ClinicalTrials.gov. Erhältlich unterURL: http://clinicaltrials.gov/ct2/info/about [Abgerufen 30.12.10]
21. McCray AT, Ide NC. Design and implementation of a national clinical trials registry. J Am Med Inform Assoc 2000; 7 (3): 313-23 (Pubitemid 30314119)
22. Fallowfield LJ, Harper P. Health-related quality of life in patients undergoing drug therapy for adVanced non-smallcell lung cancer. Lung Cancer 2005; 48 (3): 365-77 (Pubitemid 40693623)
23. Hollen PJ, Gralla RJ, Kris MG, et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 1994; 73 (8): 2087-98
24. Glossmann JP, Walshe R, Bernschein A, et al.Ö konomische Aspekte des Bronchialkarzinoms. Der Onkologe 2010; 16 (10): 1003-8
25. Brettschneider C, Lühmann D, Raspe H. Der Stellenwert von Patient-Reported Outcomes (PRO) im Kontext von Health Technology Assessment (HTA). Informative value of Patient-Reported Outcomes (PRO) in Health Technology Assessment (HTA). Schriftenreihe Health Technology Assessment Bd. 109., 1. Aufl. Kö ln: DIMDI, 2011. Erhä ltlich unter URL: berichte/hta220- bericht-de.pdf [Abgerufen 01.12.11]